Avadel Pharmaceuticals Announces FDA Approval Of LUMRYZ Extended-Release Oral Suspension For The Treatment Of Cataplexy Or Excessive Daytime Sleepiness In Patients 7 Years Of Age And Older With Narcolepsy
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals has received FDA approval for LUMRYZ, an extended-release oral suspension for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older. LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for this condition and has been granted Orphan Drug Exclusivity until 2031.
October 17, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avadel Pharmaceuticals' LUMRYZ has been approved by the FDA for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older. This approval, along with Orphan Drug Exclusivity until 2031, positions AVDL favorably in the market.
The FDA approval of LUMRYZ significantly enhances Avadel's product portfolio, providing a unique offering in the narcolepsy treatment market. The Orphan Drug Exclusivity further strengthens its competitive edge, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100